Related Experiment Video
Updated: Apr 19, 2026
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
New clinical research strategies for rare gynecologic malignancies
Isabelle Ray-Coquard1, Eric Pujade-Lauraine, Jonathan A Ledermann
1aDepartment of Adult Medical Oncology, Centre Leon Berard, Université Claude Bernard, Lyon bHôpital Hôtel-Dieu, AP-HP, Université Paris Descartes, Paris, France cUCL Cancer Institute, London, UK.
Purpose Of Review:
More than 50% of all gynecologic cancers can be classified as rare tumors (defined as an incidence of <6 per 100 000) and as such represent a major challenge for clinicians.
Recent Findings:
The rapidly increasing number of targeted therapies provides a unique opportunity to improve treatment options of rare gynecologic cancers; however, their low frequency makes it difficult to test these new agents. Harmonization of medical practices and novel trial designs are needed to identify and develop new treatments for rare gynecologic tumors.
Summary:
This requires international partnerships, harmonization of treatment recommendations, and international collaborations to overcome existing regulatory barriers in international trials. Whereas randomized trials may be possible in some rare tumor types, there are others for which conducting even single arm studies may be challenging. For these very rare tumors, robust collection of data through national registries could lead to improvements in treatment.
Insights
Rare gynecologic cancers pose clinical challenges. Developing targeted therapies requires international collaboration, harmonized practices, and innovative trial designs, especially for very rare tumor types.
Area of Science:
- Gynecologic Oncology
- Rare Cancers
- Clinical Trial Design
Background:
- Over 50% of gynecologic cancers are classified as rare, defined by an incidence of less than 6 per 100,000.
- Rare gynecologic tumors present significant challenges for clinical management and treatment development.
Purpose of the Study:
- To address the challenges in treating rare gynecologic cancers.
- To explore strategies for developing and testing targeted therapies for rare gynecologic tumors.
Main Methods:
- Review of current challenges and opportunities in rare gynecologic cancer treatment.
- Discussion of the need for harmonized medical practices and novel clinical trial designs.
Main Results:
- Targeted therapies offer potential for rare gynecologic cancers, but their low frequency impedes clinical testing.
- Harmonization of practices and innovative trial designs are crucial for advancing treatment options.
Conclusions:
- International partnerships and harmonized treatment recommendations are essential to overcome regulatory barriers in global clinical trials.
- For extremely rare tumors, national registries are vital for robust data collection to improve patient outcomes.
- While randomized trials may be feasible for some rare types, single-arm studies may also face challenges, necessitating alternative data strategies.
